Basic Information
| LncRNA/CircRNA Name | C5orf66-AS1 |
| Synonyms | NA |
| Region | GRCh38_5:135038831-135040047 |
| Ensemble | ENSG00000249082 |
| Refseq | NR_105049 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR etc. |
| Sample | samples of GC and tumor-adjacent non-cancerous tissues.cell lines(BGC823, MGC803, SGC7901, AGS, MKN28, and MKN45) |
| Expression Pattern | down-regulated |
| Function Description | C5orf66-AS1 expression was downregulated in GC cells compared to that in adjacent normal tissues. Serum C5orf66-AS1 levels were significantly lower in GC patients than in superficial gastritis (GS) and atrophic gastritis (GA) patients.Decreased expression levels of serum C5orf66-AS1 can be utilized for diagnosis of GC, especially for early diagnosis. The low level of serum C5orf66-AS1 indicated poor biological behavior of tumors in GC patients. In addition, C5orf66-AS1 can inhibit GC cell proliferation, migration, and invasion. |
| Pubmed ID | 32308414 |
| Year | 2020 |
| Title | Evaluation of C5orf66-AS1 as a Potential Biomarker for Predicting Early Gastric Cancer and Its Role in Gastric Carcinogenesis |
External Links
| Links for C5orf66-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |